Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

Author： Gardam M.A. Keystone E.C. Menzies R. Manners S. Skamene E. Long R. Vinh D.C.

Publisher： Elsevier

ISSN： 1473-3099

Source： The Lancet Infectious Diseases, Vol.3, Iss.3, 2003-03, pp. : 148-155

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-Cytokine Strategies beyond Anti-Tumour Necrosis Factor-α Therapy: Pathophysiology and Clinical Implications

Digestive Diseases, Vol. 35, Iss. 1-2, 2017-02 ,pp. : 5-12

Karger

Access to resources Recommend Favorite

Potential Effect of Anti-Tumour Necrosis Factor-Alpha Treatment on Reducing the Cardiovascular Risk Related to Rheumatoid Arthritis

Current Vascular Pharmacology, Vol. 8, Iss. 2, 2010-01 ,pp. : 285-292

Bentham Science Publishers

Access to resources Recommend Favorite

Staphylococcus aureus thymic abscesses associated with anti-tumour necrosis factor therapy

By Osiri M. Tantawichien T.

Scandinavian Journal of Rheumatology, Vol. 36, Iss. 4, 2007-01 ,pp. : 320-321

Informa Healthcare

Access to resources Recommend Favorite

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis

By Hishitani Y Ogata A Shima Y Hirano T Ebina K Kunugiza Y Shi K Narazaki M Hagihara K Tomita T Yoshikawa H Tanaka T Kumanogoh A

Scandinavian Journal of Rheumatology, Vol. 42, Iss. 4, 2013-08 ,pp. : 253-259

Informa Healthcare

Access to resources Recommend Favorite

Change in Gait Deviation Index after anti-tumour necrosis factor-α treatment in individuals with rheumatoid arthritis: a pilot study

By Broström EW Esbjörnsson A-C Heideken J von Larsson P Wretenberg P Iversen M

Scandinavian Journal of Rheumatology, Vol. 42, Iss. 5, 2013-10 ,pp. : 356-361

Informa Healthcare

Access to resources Recommend Favorite